13/11/2019 12:13 am Welcome to isteroids.com - BLOG

Thursday 29, Jul 2010

  Low doses of steroids can help myeloma patients

Posted By
Pin it Share on Tumblr

Low doses of steroids can help myeloma patientsAccording to results of Eastern Cooperative Oncology Group Phase III clinical trial E4A03 for multiple myeloma, patients with multiple myeloma can experience dramatically improved results when they are administered with a combination of lenalidomide and low-dose dexamethasone therapy when compared to a combination of lenalidomide plus high-dose dexamethasone.

This finding was reported by S. Vincent Rajkumar, M.D. at the American Society of Hematology‘s annual meeting.

Dr. Rajkumar, Mayo Clinic Cancer Center hematologist and lead investigator of the study, noted that it is surprising to know that side effects are increased and survival rate is reduced when high doses of steroids are administered.

Thursday 22, Jul 2010

  A combination of drugs may do the trick for multiple myeloma

Posted By
Pin it Share on Tumblr

A combination of drugs may do the trick for multiple myelomaLenalidomide and Dexamethasone, two drugs when taken in a combination, can prove useful for providing significant relief to patients afflicted with multiple myeloma. This finding was disclosed by a study that was conducted at 44 centers in the United States and Canada and involved 353 patients with myeloma.

Progression of myeloma can be slowed down with the pairing of a new derivative of thalidomide with a steroid and this combination could prolong lives of patients who have relapsed from treatments in the past.

Lead author Donna Weber, M.D., associate professor in the Department of Lymphoma and Myeloma at the University of Texas M. D. Anderson Cancer Center, remarked that this combination can do the trick particularly when the disease becomes immune to one therapy.

Tuesday 22, Jun 2010

  Drug combination effective to treat patients with multiple myeloma

Posted By
Pin it Share on Tumblr

Drug combination effective to treat patients with multiple myelomaDuring a study conducted at 44 centers in the United States and Canada and involving 353 patients with myeloma, it was found that a combination of drugs lenalidomide and dexamethasone could be useful for treating patients.

It was found during the study that pairing a new derivative of thalidomide with a steroid could slow down the progress of multiple myeloma along with prolonging lives of patients who have earlier relapsed from past treatments.

It was remarked by lead author Donna Weber, M.D., associate professor in the Department of Lymphoma and Myeloma at the University of Texas M. D. Anderson Cancer Center that these combinational drugs are effective as the disease may become immune to one therapy.

Tuesday 20, Apr 2010

  Distinct survival benefit possible with low steroid doses

Posted By
Pin it Share on Tumblr

Distinct survival benefit possible with low steroid dosesResults of Eastern Cooperative Oncology Group Phase III clinical trial E4A03 for multiple myeloma show significantly improved overall survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone. This finding was reported by S. Vincent Rajkumar, M.D. at the American Society of Hematology’s annual meeting.

Presently, lenalidomide and high-dose dexamethasone, referred to as Rev/Dex, is prescribed as a second-line myeloma treatment.

Dr. Rajkumar said that the finding is a major advance for treating cancer besides offering a new direction to the researchers to explore that more is not necessarily better.

Tuesday 16, Feb 2010

  Lenalidomide and Dexamethasone combination useful for treating multiple myeloma patients

Posted By
Pin it Share on Tumblr

Lenalidomide and Dexamethasone combination useful for treating multiple myeloma patientsMultiple myeloma can be effectively treated by using a combination of lenalidomide and dexamethasone, according to a study that involved 353 patients with myeloma and conducted at 44 centers in the United States and Canada.

It was revealed during the study that pairing a new thalidomide derivative with a steroid can slow down the progression of multiple myeloma besides prolonging the lives of patients who have relapsed from earlier treatments.

Lead author Donna Weber, M.D., associate professor in the Department of Lymphoma and Myeloma at The University of Texas M. D. Anderson Cancer Center, said that the combination seems to be effective as the disease may become immune to one therapy.

Wednesday 02, Sep 2009

  Lenalidomide and dexamethasone effectual against multiple myeloma

Posted By
Pin it Share on Tumblr

Lenalidomide and dexamethasone effectual against multiple myeloma The combination of lenalidomide and dexamethasone is effectual against multiple myeloma: this was a fact that was revealed after a study involving 353 patients with myeloma was conducted at 44 centers in the United States and Canada.

The study also found out that pairing a new thalidomide derivative with a steroid can considerably slowdown any further progression of multiple myeloma, which is an incurable bone marrow cancer. It was also revealed that this combination may also prove its worth to prolong lives of patients who have relapsed from previous treatments.

It was remarked by lead author Donna Weber, M.D., Associate Professor in the Department of Lymphoma and Myeloma at The University of Texas M. D. Anderson Cancer Center that a combination of medical drugs may prove to be beneficial in ongoing treatment as a disease may become resistant to one drug.

Tuesday 18, Aug 2009

  Combination of dexamethasone, Velcade, and lenalidomide effective for multiple myeloma

Posted By
Pin it Share on Tumblr

Combination of dexamethasone, Velcade, and lenalidomide effective for multiple myelomaAccording to a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology, a new combo of Velcade with dexamethasone and lenalidomide can prove to be effective for patients who have been recently diagnosed with multiple myeloma.

The combination of these three drugs is effective for treating multiple myeloma patients who have relapsed after failing to respond to standard treatment therapies or after successful treatment.

From News-Medical.Net:

The three-pronged regimen of Velcade, lenalidomide (Revlimid) and dexamethasone – referred to as Rev/Vel/Dex – has achieved an overall response rate of 98 percent in 42 patients evaluated thus far in a Phase 1-2 trial, said Paul Richardson, MD, of Dana-Farber and the study’s principal investigator. He added that 52 percent of the patients had high quality responses (very good partial response or better), with 30 percent achieving complete response to date.

“These may be some of the best response rates we’ve seen to date with up-front therapies, and although these are preliminary results, they are extremely promising,” Richardson said. The patients were previously untreated when they received the Rev/Vel/Dex combination.

Velcade is a “smart” drug known as a proteasome inhibitor that blocks the myeloma cells’ waste disposal system, creating an accumulation of toxic compounds that poison the cell. Revlimid is a chemical relative of thalidomide that affects several pathways in cancer cells, including immune mechanisms and blood vessel growth to tumors. Dexamethasone is a steroid hormone that counters inflammation and is used to treat hematologic malignancies such as myeloma. Studies leading to the trial of the three drugs in combination were carried out at Dana-Farber.

The findings are expected to offer much-awaited relief to patients with multiple myeloma, who have been expecting an effective treatment methodology for the last many years.

Monday 29, Jun 2009

  Trials for Low-dose Steroid Treatment prove effective for Bone Marrow Cancer

Posted By
Pin it Share on Tumblr

Trials for Low-dose Steroid Treatment prove effective for Bone Marrow CancerIn a clinical trial that was conducted by the Eastern Cooperative Oncology Group (ECOG) and sponsored by the National Cancer Institute (NCI) and part of the National Institutes of Health, it was revealed that a low dosage regimen of steroids can prove to be an excellent option for treating bone marrow cancer patients rather than persisting for the standard dose of dexamethasone.

The trial revealed that low doses of dexamethasone, a steroid, with lenalidomide can work wonders on patients who are fighting against newly diagnosed multiple myeloma. It was also revealed that the combination of dexamethasone and lenalidomide brought fewer side-effects.

As per noted study chair Vincent Rajkumar, the combination of lenalidomide plus low-dose dexamethasone is extremely positive and truly represents a potential step ahead for treating multiple myeloma.

Wednesday 24, Jun 2009

  Low Doses of Steroids with Lenalidomide Prolong Survival of Patients with Multiple Myeloma

Posted By
Pin it Share on Tumblr

Low Doses of Steroids with Lenalidomide Prolong Survival of Patients with Multiple MyelomaAs per a randomized clinical trial for patients with newly diagnosed multiple myeloma, low doses of the steroid, dexamethasone, along with lenalidomide can help in prolonging survival for multiple myeloma patients.

The trial was conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG) and sponsored by the National Cancer Institute (NCI).

It was revealed during the trial that a combination of dexamethasone (low dosages) and lenalidomide is far effective than lenalidomide and higher doses of dexamethasone.

As per noted study chair Vincent Rajkumar, M.D., Mayo Clinic, Rochester, Minn, these results are expected to have major implications for therapy relevant to multiple myeloma, a cancer typically found in bone marrow.

Rajkumar remarked that the results of this trial are very positive and can be seen as a potential real step ahead in the treatment of multiple myeloma.

Monday 08, Jun 2009

  Lenalidomide and low doses of steroids helpful for multiple myeloma treatment

Posted By
Pin it Share on Tumblr

Lenalidomide and low doses of steroids helpful for multiple myeloma treatmentAs per a randomized clinic trial for patients with newly diagnosed multiple myeloma, low doses of dexamethasone (Decadron ®) along with lenalidomide (Revlimid ®) are helpful in improving survival rates to a considerable extent. This combination proved to out to a better option against a combination of lenalidomide and a high dosage of dexamethasone.

The treatment method will help all those patients suffering from Multiple myeloma, which is a cancer of plasma cells found in blood and bone marrow.

The trial was a part of the National Institutes of Health, which was sponsored by the National Cancer Institute (NCI), and was conducted by researchers led by the Eastern Cooperative Oncology Group (ECOG).

The new findings have been welcomed by all segments of the medical world and is seen as a real step forward in the right direction for treatment of Multiple Myeloma, as per study chair Vincent Rajkumar, M.D., Mayo Clinic, Rochester, Minn.